Giles Campion
Nessuna posizione attualmente
Patrimonio netto: 79 200 $ in data 31/07/2023
Provenienza dei contatti di primo grado di Giles Campion
| Entità | Tipo di entità | Settore Industriale | |
|---|---|---|---|
| Public Company | Miscellaneous Commercial Services | 15 | |
| Extinct | Biotechnology | 13 | |
| Public Company | Biotechnology | 9 |
Grafico delle società connesse in secondo grado
Relazione in diverse aziende
Società connesse a Giles Campion tramite i suoi contatti personali
| Società | Settore | Persone collegate | Posizione principale |
|---|---|---|---|
| ENZON PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director of Finance/CFO Corporate Officer/Principal | |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Medical Specialties | Director of Finance/CFO Director of Finance/CFO | |
Biothera, Inc.
 Biothera, Inc. Miscellaneous Commercial ServicesCommercial Services Biothera, Inc. develops natural gluco polysaccharide that engages and directs natural innate immune systems. The company was founded by Daniel Conners in 1997 and is headquartered in Eagan, MN. | Miscellaneous Commercial Services | Director/Board Member | |
Biotechnology Innovation Organization
 Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member Director/Board Member Investor Relations Contact | |
Omthera Pharmaceuticals, Inc.
 Omthera Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Omthera Pharmaceuticals, Inc. operates as pharmaceuticals company which focuses on the clinical development of new therapies for dyslipidemia. The company was founded by Jerry Wisler and Michael Davidson in 2008 and is headquartered in Princeton, NJ. | Pharmaceuticals: Major | Director/Board Member Founder | |
| ARATANA THERAPEUTICS INC | Pharmaceuticals: Major | Chief Executive Officer Director of Finance/CFO | |
| AFFIMED N.V. | Biotechnology | Director/Board Member Director/Board Member | |
| NOVARTIS AG | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
| Dartmouth College | College/University | Undergraduate Degree Undergraduate Degree | |
Chicago Center for Clinical Research
 Chicago Center for Clinical Research Miscellaneous Commercial ServicesCommercial Services Part of CRA Holdings LLC, Chicago Center for Clinical Research is an American company that provides clinical research services. The private company was founded by Michael H. Davidson. | Miscellaneous Commercial Services | Chief Executive Officer | |
| VALERIO THERAPEUTICS | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| The University of Edinburgh | College/University | Graduate Degree Undergraduate Degree | |
| The University of Chicago | College/University | Masters Business Admin Corporate Officer/Principal | |
The Ohio State University
 The Ohio State University Other Consumer ServicesConsumer Services Global Factory, Inc. provides collaborative manufacturing execution systems. The firm's software gather, organize & analyze demand, production & quality data from various sources and monitor key indicators & execute business processes to control, manage & optimize distributed manufacturing operations. The company was founded in 1999 and is headquartered in Santa Clara, CA. | College/University | Doctorate Degree | |
| INSEAD | College/University | Masters Business Admin Masters Business Admin | |
| ZEALAND PHARMA A/S | Pharmaceuticals: Major | Director/Board Member Chief Executive Officer | |
| Erasmus University Rotterdam | College/University | Doctorate Degree Doctorate Degree | |
| University of Utrecht | College/University | Graduate Degree Graduate Degree Doctorate Degree Doctorate Degree | |
| Katholieke Universiteit Leuven | College/University | Doctorate Degree | |
Genzyme Europe BV
 Genzyme Europe BV Pharmaceuticals: MajorHealth Technology Part of Sanofi, Genzyme Europe BV is a Dutch company that develops and manufactures pharmaceutical and biotherapeutic products. The private company is based in Amsterdam, Netherlands. | Pharmaceuticals: Major | Corporate Officer/Principal Sales & Marketing | |
| PHARNEXT SCA | Biotechnology | Chief Executive Officer Director of Finance/CFO | |
Abcentra, Inc.
 Abcentra, Inc. Miscellaneous Commercial ServicesCommercial Services Abcentra, Inc. is an American clinical-stage biopharmaceutical company that specializes in developing novel antibody therapies for inflammatory diseases, with a particular focus on cardiovascular disease. The private company's patented technology allows for the targeting of oxidized lipoproteins and associated inflammatory responses. Abcentra's pipeline focuses on patient populations with high-risk of cardiometabolic complications that are exacerbated by chronic inflammation, including patients with inflammatory diseases and patients with residual inflammation. The company's lead compound, orticumab, is a novel monoclonal antibody that blocks inflammation from oxidized low-density lipoprotein and is slated to begin a phase 2 study later this year. Kevin B. Bacon has been the CEO of the company since 2020. | Miscellaneous Commercial Services | Director/Board Member | |
| ARDELYX, INC. | Pharmaceuticals: Major | Chairman Director/Board Member | |
| Harvard Medical School | College/University | Corporate Officer/Principal Doctorate Degree | |
Ovizio Imaging Systems SA
 Ovizio Imaging Systems SA Electronic ComponentsElectronic Technology Ovizio Imaging Systems SA develops and markets imaging systems and sensors. Its microscopes include iLine F, iLine M, iLine S and QMod. The company was founded by Catherine Yourassowsky, Frank Dubois, Philip Mathuis and Serge Jooris in December 2009 and is headquartered in Brussels, Belgium. | Electronic Components | Director/Board Member | |
| AURINIA PHARMACEUTICALS INC. | Biotechnology | Investor Relations Contact Director/Board Member | |
| DIMENSION THERAPEUTICS INC | Biotechnology | Chief Executive Officer | |
Transcelerate Biopharma, Inc.
 Transcelerate Biopharma, Inc. BiotechnologyHealth Technology Transcelerate Biopharma, Inc. is a non-profit consortium that collaborates with pharmaceutical and biotechnology companies to improve the delivery of new medicines. The non-profit company is based in King of Prussia, PA. The organization's mission is to identify, prioritize, design, and facilitate implementation of solutions to drive the efficient, effective, and high-quality delivery of new medicines. Transcelerate has 20 member companies and 30+ initiatives focused on improving the patient and site experience, enhancing sponsor efficiencies and drug safety, and harmonizing processes and sharing information. The company was founded by Garry Arthur Neil, and Janice Chang has been the CEO of the company since 2014. | Biotechnology | Chairman | |
DROIA NV
 DROIA NV Investment ManagersFinance DROIA NV (DROIA) is an Independent Venture Capital firm founded in 2011 by Bart van Hooland. The firm is headquartered in Meise with additional office in Luxembourg. | Investment Managers | Private Equity Investor | |
| MEREO BIOPHARMA GROUP PLC | Biotechnology | Chairman Director/Board Member | |
| Primix Bio Ventures BV | Chief Executive Officer | ||
Tusk Therapeutics NV
 Tusk Therapeutics NV Miscellaneous Commercial ServicesCommercial Services Part of Tusk Therapeutics SA, Tusk Therapeutics NV operates as a research organization. The private company is based in Vlaams Brabant, Belgium. | Miscellaneous Commercial Services | Chief Executive Officer | |
| PHARVARIS N.V. | Pharmaceuticals: Major | Founder Director/Board Member Founder Founder | |
Tusk Therapeutics SA
 Tusk Therapeutics SA Pharmaceuticals: MajorHealth Technology Tusk Therapeutics SA develops and manufactures therapeutic products. The private company is based in Luxembourg, Luxembourg. and has subsidiaries in Belgium. Luc Dochez has been the CEO of the Luxembourger company since 2015. | Pharmaceuticals: Major | Chief Executive Officer | |
| Premis BV | Chief Executive Officer | ||
Tusk Therapeutics Ltd.
 Tusk Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Tusk Therapeutics Ltd. operates as a immuno-oncology company, focused on discovering and developing therapeutic antibodies. It provides immune modulating cancer therapeutics. The company is headquartered in Stevenage, the United kingdom. | Pharmaceuticals: Major | Chief Executive Officer | |
Highlight Therapeutics SL
 Highlight Therapeutics SL Pharmaceuticals: MajorHealth Technology Highlight Therapeutics develops ribonucleic acid-based therapies and novel targets in cancer and immune cells. Its product BO-112, induces immunogenic cell death in solid tumors and simultaneously activates the innate immune system to ensure optimal antigen processing and presentation to the adaptive immune system. The company was founded by Damia tormo Carulla and is headquartered in Paterna, Spain. | Pharmaceuticals: Major | Director/Board Member | |
QurAlis Corp.
 QurAlis Corp. Pharmaceuticals: MajorHealth Technology QurAlis Corp. engages in discovering and developing new therapies for amyotrophic lateral sclerosis and other neurological diseases. It offers therapeutic programs and targets, and biomarkers. The company was founded by Clifford Woolf, Kevin Eggan, Jonathan J. Fleming, and Kasper Roet and is headquartered in North Cambridge, MA. | Pharmaceuticals: Major | Director/Board Member | |
Affimed GmbH
 Affimed GmbH Miscellaneous Commercial ServicesCommercial Services Part of Affimed NV, Affimed GmbH is a clinical leader in innate immuno-oncology. The private company, based in Heidelberg, Germany, develops proprietary cancer-targeting bispecific antibodies that activate the innate immune system to kill tumor cells. Affimed leads clinical development of innate cell engagers for solid/hematologic tumors as monotherapy, in combination with NK cells or with checkpoint inhibitors. Adolf Hoess has been the CEO of the German company since 2010. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
Volastra Therapeutics, Inc.
 Volastra Therapeutics, Inc. BiotechnologyHealth Technology Volastra Therapeutics, Inc. develops novel therapies for patients with metastatic cancers. The company was founded by Lewis Cantley, Samuel Bakhoum and Olivier Elemento and is headquartered in Boston, MA. | Biotechnology | Director/Board Member | |
Vico Therapeutics BV
 Vico Therapeutics BV BiotechnologyHealth Technology Vico Therapeutics BV is a private biotech company based in Leiden, Netherlands that focuses on developing RNA modulating therapies for rare severe neurological disorders. The Dutch company's antisense oligonucleotide platform (AON) is directed towards different forms of spinocerebellar ataxia (SCA) and Huntington disease (HD), while its early discovery RNA editing platform is directed towards Rett syndrome. Vico Therapeutics was founded in 2019 by Luc Dochez, Josh Mandel-Brehm, Gail Mandel, and Dr. Judith van Deutekom, who have strong academic reputations and vast industry experience. Micah Mackison has been the CEO of the company since 2022. | Biotechnology | Director/Board Member Founder | |
Montis Biosciences BV
 Montis Biosciences BV BiotechnologyHealth Technology Montis Biosciences BV engages in the development of immune-oncology therapeutics targetting the intersection between vascular dysfunction and immune suppression to treat solid tumors. It offers target screening and assay platform to discover novel targets modulating interactions between tumor endothelial cells and perivascular macrophages. The company was founded by Peter Carmeliet and Massimiliano Mazzone and is headquartered in Meise, Belgium. | Biotechnology | Chairman | |
Muna Therapeutics ApS
 Muna Therapeutics ApS Medical/Nursing ServicesHealth Services Muna Therapeutics ApS is a Danish private biopharmaceutical company that discovers and develops therapies to slow or stop neurodegenerative diseases such as Alzheimer's, frontotemporal dementia, and Parkinson's. Muna Therapeutics is based in Copenhagen, DK and was founded in 2020 by Simon Glerup and Bart de Strooper. The company focuses on identifying new medicines to preserve cognition and other brain functions and enhance resilience to these diseases. Rita Balice-Gordon has been the CEO of the company since 2020. | Medical/Nursing Services | Director/Board Member | |
Pharvaris GmbH
 Pharvaris GmbH Pharmaceuticals: MajorHealth Technology Pharvaris GmbH operates as a clinical-stage company. It specializes in medicinal chemistry, drug discovery and development and hereditary angioedema. The company was founded by Berndt A. E. Modig, Jochen Knolle, Anne Lesage and Hans G. C. P. Schikan in October 2015 and is headquartered in Zug, Switzerland. | Pharmaceuticals: Major | Founder Director/Board Member Founder | |
Mahzi Therapeutics, Inc.
 Mahzi Therapeutics, Inc. BiotechnologyHealth Technology Mahzi Therapeutics is a private biotechnology company that focuses on genetic therapies for rare genetic neurodevelopmental disorders. The company was founded by Yael Weiss and is based in San Mateo, CA. The company unites patient and family groups, academic researchers, diagnostic companies, other industry members, and its internal team of experts to develop therapies for patients with these serious diseases. Mahzi's team is experienced in all aspects of biopharmaceutical research, development, and manufacturing and is driven to make a difference in the lives of patients with rare genetic diseases. Yael Weiss has been the CEO since incorporation. | Biotechnology | Director/Board Member | |
Cascador Health BV
 Cascador Health BV Packaged SoftwareTechnology Services Cascador Health BV is a Belgian company that aims to unlock the true value of patient data for better healthcare and better health for individual patients. The company is based in Tielrode, Belgium. The company wants to bridge the gap between data providers and research/industry and become the reference for projects. It was founded in 2021 and the CEO is Philip Taillieu. | Packaged Software | Director/Board Member | |
| Summation Bio, Inc. | Director/Board Member |
Statistiche
Distribuzione geografica
| Stati Uniti | 20 |
| Belgio | 9 |
| Paesi Bassi | 8 |
| Francia | 5 |
| Regno Unito | 4 |
Settori
| Health Technology | 29 |
| Consumer Services | 10 |
| Commercial Services | 7 |
| Electronic Technology | 2 |
| Finance | 2 |
Posizioni
| Director/Board Member | 285 |
| Independent Dir/Board Member | 75 |
| Corporate Officer/Principal | 74 |
| Chairman | 58 |
| Chief Executive Officer | 52 |
Contatti più connessi
| Insiders | |
|---|---|
| Annalisa Jenkins | 51 |
| David Mott | 45 |
| William Young | 32 |
| Michael Wyzga | 31 |
| Rémi Droller | 29 |
| David Pyott | 27 |
| Michael Davidson | 27 |
| Luc Dochez | 26 |
| Leonard Post | 25 |
| Berndt A. E. Modig | 23 |
| Johannes G. C. P. Schikan | 22 |
| David Solomon | 22 |
| Craig Tooman | 22 |
| John Paul de Koning | 21 |
| Eric Floyd | 18 |
- Borsa valori
- Insiders
- Giles Campion
- Connessioni Società
